Ten post jest także dostępny w języku: polski
Polpharma Biologics Group’s joint venture has entered into an agreement with Teva to commercialise a biosimilar drug to Ranibizumab. The biologic drug is used in ophthalmic therapy.
A partnership agreement between Teva and a joint venture with Santo Holding (Strungmann Group) of Polpharma Biologics Group will see the commercialisation of the biosimilar drug Ranibizumab (Lucentis).
The agreement provides for the development and manufacturing of a biosimilar ophthalmic drug candidate to Ranibizumab (Lucentis), under which the drug will be marketed in Europe, Canada, Israel and New Zealand. In 2019, Bioeq has entered into an agreement with Coherus BioSciences, Inc. to commercialise the drug in the US.
Ranibizumab biosimilar drug
The licence for the biosimilar drug Ranibizumab (FYB201) was obtained from German company Formycon AG. The development work on the drug was carried out by Bioeq AG. It is worth mentioning that the results of Phase III clinical trials showed that the efficacy of FYB201 treatment of patients with nAMD is comparable to that of the reference formulation Lucentis.